Stocks Health care MGNX

NASDAQ · Health care

Macrogenics Inc (MGNX)

Macrogenics Inc brought in $183M of revenue over the twelve months to June 30, 2026, up 21.9% from a year earlier. It posted a net loss of $14.6M. In fiscal 2025 capital spending exceeded operating cash flow by $83M. At June 30, 2026 it held $113.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

What Macrogenics Inc does

Macrogenics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MGNX.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Where MGNX ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Macrogenics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 3, 2026
   Employee stock plan registration S-8
2. September 3, 2026
   Exhibits 8-K/A
3. August 14, 2026
   Quarterly report 10-Q · period to June 30, 2026
4. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
5. August 13, 2026
   Quarterly results 8-K
6. August 3, 2026
   Passive stake changed SCHEDULE 13G/A
7. July 29, 2026
   Passive stake (5% or more) SCHEDULE 13G
8. July 23, 2026
   Other event 8-K
9. July 20, 2026
   Passive stake changed SCHEDULE 13G/A
10. July 8, 2026
    Executive or director change 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 21, 2026. Insider transactions on SEC

Insider trades

What the people running Macrogenics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about MGNX

What does Macrogenics Inc do?

Macrogenics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MGNX.

Is Macrogenics Inc profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $14.6M on revenue of $183M.

How much revenue does Macrogenics Inc make?

Over the twelve months to June 30, 2026 Macrogenics Inc reported revenue of $183M. That is 21.9% more than a year earlier.

When did Macrogenics Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the planned insider sale from September 21, 2026.

Similar companies

Compare MGNX with

Compare MGNX with any company

Follow MGNX

Get an email when Macrogenics Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow MGNX: get an email when it files

Where the numbers come from

Financial figures are the values Macrogenics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.